Custom CRISPR Gene Therapy Saves Baby With Rare Disease
The Facts
- KJ Muldoon of Clifton Heights, Pennsylvania, who was diagnosed with a rare genetic disorder called severe CPS1 deficiency, which affects one in a million infants at two days old, has shown significant improvement after receiving a personalized CRISPR gene editing treatment at Children's Hospital of Philadelphia.
- The medical team, led by Dr. Kiran Musunuru and Dr. Rebecca Ahrens-Nicklas, developed a customized base editing therapy within six months to correct KJ's specific genetic mutation that prevents his body from properly processing ammonia, which can be toxic to the brain.
- The experimental treatment, delivered through lipid nanoparticles to KJ's liver cells, involved three doses administered between February and April. He is the first to receive a personalized CRISPR therapy designed for a single individual.
.png&w=64&q=75 "National Institutes of Health (NIH)"){kind=small}
Sources Split
LEFT
CENTER
RIGHT
+1
+2
ESTAB
CRIT
CENTER
PRO
ESTAB
The Spin
Techno-optimist narrative
This groundbreaking achievement highlights the remarkable potential of personalized gene editing to revolutionize medicine. The swift development time and successful implementation prove that custom genetic treatments can be both feasible and practical, potentially offering hope to millions affected by rare genetic disorders who currently have no viable treatment options.
Techno-skeptic narrative
The experimental nature of this treatment raises significant concerns about long-term safety and efficacy. Without comprehensive long-term studies, the risks of unintended genetic changes remain unknown, and the high cost of personalized treatments could create accessibility barriers for many patients who need them.
Metaculus Prediction
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.18.3